Skip to Content
Merck
All Photos(1)

Documents

354R-1

Sigma-Aldrich

TFE3 (MRQ-37) Rabbit Monoclonal Antibody

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

MRQ-37, monoclonal

description

For In Vitro Diagnostic Use in Select Regions (See Chart)

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (354R-14)
vial of 0.5 mL concentrate (354R-15)
bottle of 1.0 mL predilute (354R-17)
vial of 1.0 mL concentrate (354R-16)
bottle of 7.0 mL predilute (354R-18)

manufacturer/tradename

Cell Marque

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

isotype

IgG

control

ASPS, melanoma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

Gene Information

human ... TFE3(7030)

General description

Xp11 translocation renal cell carcinomas (RCC) are a recently recognized subset of RCC, characterized by chromosome translocations involving the Xp11.2 break point and resulting in gene fusions involving the TFE3 transcription factor gene that maps to this locus. Xp11 translocation RCC represents the most common type of RCC in children, but is less frequent on a percentage basis in adults. Morphologically, these neoplasms frequently show papillary architecture and clear cytoplasm, and frequently have associated psammoma bodies. Immunohistochemically, these neoplasms under-expresses epithelial markers such as anti-cytokeratin and anti-epithelial membrane antigen (anti-EMA) compared with typical adult type RCC. The most sensitive and specific immunohistochemical marker for the Xp11 translocation RCC is nuclear labeling of TFE3 protein, which reflects over-expression of the resulting fusion proteins relative to native TFE3. Alveolar soft part sarcoma (ASPS) is an uncommon soft tissue sarcoma of undertain differentiation. It presents in younger patients, often in the extremities. Despite relatively high rates of metastasis, patients often experience prolonged survival in the metastatic setting relative to others. The hallmark of ASPS is a chromosomal rearrangement at 17q25 and Xp11.2 engendering an ASPSCR1-TFE3 fusion gene responsible for an aberrant transcription factor presumably enabling pathogenesis.This aberrant chimeric transcription factor retains the N-terminal DNA binding domain encoded by TFE3 while the ASPSCR1 encoded portion probably provides domain(s) modulating gene expression. The presence of this ′super-activated′ transcription factor may induce the expression of numerous molecules contributing to ASPS diagnosis, progression, and metastasis.

Quality


IVD

IVD

IVD

RUO

Linkage

TFE3 Positive Control Slides, Product No. 354S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Preparation Note

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alexander J Lazar et al.
Histopathology, 55(6), 750-755 (2009-12-17)
The molecular signature of alveolar soft part sarcoma (ASPS) is a specific der(17)t(X;17)(p11.2;q25) translocation, resulting in a chimeric transcription factor (ASPSCR1-TFE3). When this disease is no longer amenable to surgical curative intervention, uniformly efficacious therapies are lacking. The aim of
The evolving story of renal translocation carcinomas.
Pedram Argani et al.
American journal of clinical pathology, 126(3), 332-334 (2006-08-02)
Pedram Argani et al.
Clinics in laboratory medicine, 25(2), 363-378 (2005-04-26)
A significant proportion of RCCs of children and young adults bear specific chromosome translocations that result in gene fusions that involve members of the MiTF/TFE transcription factor family. These include the Xp11-translocation carcinomas, which bear TFE3 gene fusions, and the
Pedram Argani et al.
The American journal of surgical pathology, 27(6), 750-761 (2003-05-27)
We report the aberrantly strong nuclear immunoreactivity for the C-terminal portion of TFE3 protein in tumors characterized by chromosome translocations involving the TFE3 gene at Xp11.2. This group of tumors includes alveolar soft part sarcoma and a specific subset of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service